Tonix Pharmaceuticals Holding (TNXP) Interest Coverage Ratio (2011 - 2026)
Tonix Pharmaceuticals Holding's (TNXP) quarterly Interest Coverage Ratio came in at 288.45 in Q1 2026, down 110.22% year-on-year from 2822.26 in Q1 2025, and down 171.09% quarter-over-quarter from 405.76 in Q4 2025.
Tonix Pharmaceuticals Holding (TNXP) Interest Coverage Ratio (2011 - 2026) Analysis & Trends
Tonix Pharmaceuticals Holding's Interest Coverage Ratio history runs 16 years deep, the most recent figure standing at 288.45 for Q1 2026.
- On a quarterly basis, Interest Coverage Ratio fell 110.22% year-over-year to 288.45 in Q1 2026; TTM through Mar 2026 was 1049.9, a 257.15% decrease from a year earlier, with the FY2025 full-year figure at 20.58, down 846.36% from the prior year.
- Interest Coverage Ratio fell to 288.45 in Q1 2026 per TNXP's latest filing, from 405.76 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 405.76 in Q4 2025 and bottomed at 944.77 in Q3 2025.
- The 5-year median for Interest Coverage Ratio is 186.11 (2022), against an average of 195.52.
- Biggest YoY gain for Interest Coverage Ratio was 226.35% in 2025; the steepest drop was 8179.05% in 2025.
- Year by year, Interest Coverage Ratio stood at 216.74 in 2022, then slipped by 3.35% to 224.01 in 2023, then plunged by 43.36% to 321.14 in 2024, then soared by 226.35% to 405.76 in 2025, then tumbled by 171.09% to 288.45 in 2026.
- Per Business Quant, the three latest TNXP Interest Coverage Ratio figures stand at 288.45 (Q1 2026), 405.76 (Q4 2025), and 944.77 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 658.42 |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -157.58 |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 7.60 |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 2.71 |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 22.72 |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -0.38 |
| 10 | Tonix Pharmaceuticals Holding | 142.07 Mn | 142.07 Mn | 5.30 Mn | -288.45 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -288.45 |
| Dec 31, 2025 | 405.76 |
| Sep 30, 2025 | -944.77 |
| Jun 30, 2025 | -673.71 |
| Mar 31, 2025 | -137.21 |
| Dec 31, 2024 | -321.14 |
| Sep 30, 2024 | -11.41 |
| Jun 30, 2024 | -49.18 |
| Mar 31, 2024 | -11.95 |
| Dec 31, 2023 | -224.01 |
| Sep 30, 2023 | -22.45 |
| Jun 30, 2023 | -204.24 |
| Mar 31, 2023 | -245.67 |
| Dec 31, 2022 | -216.74 |
| Sep 30, 2022 | -186.11 |
| Jun 30, 2022 | -23.15 |
| Mar 31, 2022 | -169.46 |
| Dec 31, 2021 | -192.67 |
| Sep 30, 2021 | -127.83 |
| Jun 30, 2021 | -981.75 |